Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: The Role of Combination Checkpoint Blockade Is Evolving in MSI-H mCRC: With Elena Élez, MD, PhD
Description: In our exclusive interview, Dr Élez discussed recent data comparing nivolumab (Opdivo) monotherapy with nivolumab plus ipilimumab (Yervoy) across multiple lines of therapy in patients with MSI-H mCRC. She detailed efficacy and quality‑of‑life outcomes, noting that the combination appeared to offer enhanced clinical benefit without a negative effect on tolerability. Dr Élez also highlighted the importance of tailoring immunotherapy strategies based on patient characteristics and treatment goals and reflected on the nuances of sequencing single‑agent vs combination checkpoint blockade.